… Taken together, we speculate that the pathway reactivation in KRAS-mutant cell lines may
be broadly and dominantly mediated by SHP2 though they may exhibit differential sensitivity …

… Collectively these data demonstrate that KRAS mutant tumor lines respond similarly to
MEK or ERK inhibition and that pathway reactivation would be expected to limit the activity of …

… These studies overall suggest the reactivation of MAPK signaling and/or mutant KRAS-independent
activation of the PI3K pathway as common modalities to bypass KRAS G12C …

… KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. … of RAF1 as a key target to block KRAS-mutant cancers. …

… of KRAS mutations in lung cancer, the molecular techniques for identification of such mutations,
the … mechanism to reactivate RAS signaling if one of the two KRAS pathway is blocked. If …

… reactivation of ERK-dependent signaling to bypass KRAS … identified adaptive RAS pathway
feedback reactivation as a … G12C mutation and conversion to a different KRAS mutation …

… KRAS mutant cancers. In this review, we highlight the challenges and opportunities in targeting
KRAS mutant tumors … reactivation as observed with induction of phosphorylated MEK and …

… alone is not capable to suppress MAPK pathway in RAS-mutated cancers and that co-targeting
of upstream receptors might be a way to avoid pathway reactivation [26]. Two seminal …

… The mutant KRAS signalling pathway upregulates the expression of PD-L1 in tumour
cells by improving the stability of PD-L1 mRNA 102 . Although the AU-rich binding protein …

… in patients with pancreatic cancer harbouring KRAS mutations (NCT01978184, NCT01506973
… overcame pathway reactivation and was more effective than either agent alone in NRAS-…